Press Releases

Covalon Announces Voting Results from 2019 Annual and Special Meeting of Shareholders

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Mar. 8, 2019-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV; OTCQX:CVALF), an advanced medical technologies company, today announces the results of the matters voted upon at the Company’s 2019 Annual and Special Meeting of Shareholders on held March 7, 2019.

Shareholders voted in favour of all items of business and each was approved by the requisite number of votes. The matters included the election of the board of directors, the appointment of auditors, and the approval of the Company’s amended and restated stock option plan. The total number of shares represented, either in person or by proxy, totaled 10,594,797 or 47.73%. The voting results are detailed below.

               

1) Election of the Board of Directors:

 
Name of Nominee Votes FOR % Votes WITHHELD %
Abe Schwartz 9,988,856 98.772% 124,190 1.228%
Ian Brindle 9,949,587 98.384% 163,459 1.616%
Brian Pedlar 9,988,856 98.772% 124,190 1.228%
Joseph Cordiano 10,112,446 99.994% 600 0.006%
Jeffrey Mandel 9,946,687 98.355% 166,359 1.645%
Gale Pollock 10,112,546 99.995% 500 0.005%
Myrna Francis 10,112,546 99.995% 500 0.005%
John Suk 10,112,546 99.995% 500 0.005%
 
 

2) The Appointment of the Auditor:

               
  Votes FOR % Votes WITHHELD %
PricewaterhouseCoopers, LLP 10,411,207 98.981% 107,190 1.019%
 
 

3) The Approval of the Company’s Amended and Restated Stock Option Plan:

               
  Votes FOR % Votes AGAINST %
Amended and Restated Stock Option Plan 9,979,356 98.678% 133,690 1.322%
 

Final voting results of all matters voted on at the meeting will be filed on SEDAR at www.sedar.com and further details of the voted matters can be found in the Company’s management information circular with a record date of January 10, 2019.

About Covalon
Covalon Technologies Ltd. researches, develops, and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon's technologies are used to prevent, detect, and manage medical conditions in specialty areas such as infection control, vascular access, surgical procedures, advanced wound care, and medical device coatings. To learn more about Covalon, visit our website at www.covalon.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including completion of integration of the AquaGuard acquisition, the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

Source: Covalon Technologies Ltd.

Brian Pedlar, CEO, Covalon Technologies Ltd.
Email: bpedlar@covalon.com
Phone: 905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com
Twitter: @covalon